The quinolone antibiotics arose in the early 1960s, with the first examples possessing a
narrow-spectrum of activity with unfavorable pharmacokinetic properties. Over time, the …

This comprehensive State of the Art review summarizes the current published knowledge
base regarding the pathophysiology and microbiology of pulmonary disease in cystic …

Efflux pump genes and proteins are present in both antibiotic-susceptible and antibiotic-
resistant bacteria. Pumps may be specific for one substrate or may transport a range of …

The history of the development of the quinolones is described from the first quinolone,
nalidixic acid, via the first 6-fluorinated quinolone norfloxacin, to the latest extended …

The quinolone class of antimicrobial agents has generated considerable interest since its
discovery> 40 years ago. Substantial progress has been made in our understanding of the …

The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and
topoisomerase IV, both of which are involved in DNA replication. Quinolones form …

Pseudomonas aeruginosa is one of the leading causes of nosocomial infections. Severe
infections, such as pneumonia or bacteraemia, are associated with high mortality rates and …

Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases
involving resistance or intolerance to first-line antituberculosis therapy, these drugs are …

Pneumonia complicates hospitalization in 0.5 to 2.0% of patients and is associated with
considerable morbidity and mortality. Risk factors for hospital-acquired pneumonia (HAP) …

Pharmacodynamics provides a rational basis for optimizing dosing regimens by describing
the relationship between drug, host and antimicrobial effect. The successful identification of …